Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies

被引：0
|
作者：
Bar, Yael
Dedeoglu, Aylin S.
Fell, Geoffrey G.
Moffett, Natalie J.
Boyraz, Baris
Ly, Amy
Bardia, Aditya
Moy, Beverly
Ellisen, Leif W.
Isakoff, Steven J.
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[4] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1005
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies
    Bar, Yael
    Fell, Geoffrey
    Dedeoglu, Aylin
    Moffett, Natalie
    Vidula, Neelima
    Spring, Laura
    Wander, Seth A.
    Bardia, Aditya
    Ko, Naomi
    Moy, Beverly
    Ellisen, Leif W.
    Isakoff, Steven J.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [2] A rapid, non-invasive test to determine HER2-low status in triple negative breast cancer (TNBC) patients
    Cook, Daniel
    Patel, Snehal
    Whitman, John
    Hobbs, Nicole
    Lopez-Ramos, Dorys A.
    Pfeiffer, John
    Peterson, Joseph
    Pandey, Tushar
    Antony, Anuja K.
    Cole, John
    CANCER RESEARCH, 2023, 83 (07)
  • [3] The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer
    Park, Woong Ki
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeong Eon
    Yu, Jonghan
    Lee, Se Kyung
    Ryu, Jai Min
    Chae, Byung Joo
    CANCERS, 2024, 16 (14)
  • [4] Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)
    Taylor, Melissa
    Reddy, Shilpa
    Kumar, Prashanth Ashok
    Hariri, Dana
    Sokol, Ethan
    Sivakumar, Smruthy
    Quintanilha, Julia
    Pavlick, Dean
    Levy, Mia Alyce
    Ross, Jeffrey S.
    Lustberg, Maryam B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] The impact of the HER2-low status on conditional survival in patients with breast cancer
    Ma, Teng
    Liu, Changgen
    Ma, Tianyi
    Sun, Xinyi
    Cui, Jian
    Wang, Lulu
    Mao, Yan
    Wang, Haibo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [6] Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
    Domergue, C.
    Martin, E.
    Lemarie, C.
    Jezequel, P.
    Frenel, J-S.
    Augereau, P.
    Campone, M.
    Patsouris, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S428 - S429
  • [7] Study of HER2-low expression in triple-negative breast cancer
    Trung, T. Tran
    Ngoc, A. Duong Thi
    Van, T. Nguyen
    Van, T. Ta
    BREAST, 2025, 80
  • [8] Dynamics of HER2-low expression in triple-negative breast cancer
    Garrido-Castro, Ana C.
    Ngo, Lan D.
    Richardson, Edward T.
    Frangieh, Allison
    Mohammed-Abreu, Ayesha
    Hughes, Melissa E.
    Zanudo, Jorge Gomez Tejada
    Navarro, John
    Tarantino, Paolo
    Mittendorf, Elizabeth A.
    Tolaney, Sara
    King, Tari
    Winer, Eric
    Lin, Nancy U.
    Wagle, Nikhil
    CANCER RESEARCH, 2023, 83 (05)
  • [9] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06) : 1673 - 1681
  • [10] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
12345